EcoDrugPlus

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSBBBG00000012848
Gene Symbol: PPARA
3 Cross references
455 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSBBBG00000013721
Gene Symbol: PPARD
1 Cross references
420 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSBBBG00000011336
Gene Symbol: PPARG
3 Cross references
406 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSBBBG00000016857
Gene Symbol: PIK3CA
3 Cross references
274 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSBBBG00000016142
Gene Symbol: PIK3CB
3 Cross references
216 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSBBBG00000020939
Gene Symbol: PIK3CD
3 Cross references
214 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSBBBG00000001333
Gene Symbol: PIK3CG
3 Cross references
215 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSBBBG00000022256
Gene Symbol: PDE10A
3 Cross references
207 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSBBBG00000002016
Gene Symbol: PDE3A
3 Cross references
258 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSBBBG00000014623
Gene Symbol: PDE3B
3 Cross references
204 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSBBBG00000003458
Gene Symbol: PDE4A
1 Cross references
250 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSBBBG00000002710
Gene Symbol: PDE4B
3 Cross references
298 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).